Cell News and Research

RSS

Gluconeogenesis severely compromised in HCC by IL6-Stat3-mediated activation of miR-23a

As liver cancer develops, tumor cells lose the ability to produce and release glucose into the bloodstream, a key function of healthy liver cells for maintaining needed blood-sugar levels.

31 Jul 2012

New drug shows promise for Long QT syndrome

Long QT syndrome, which results from genetic mutation or certain medications, can cause the heart to beat chaotically and the affected person to die suddenly. The chaotic heartbeat is due to abnormal electrical activity in the heart. In an electrocardiogram test, this abnormality appears as a wider-than-normal QT interval, a pattern of "hills" in a map of peaks and valleys corresponding to the heart contracting and relaxing.

30 Jul 2012

Burn wound MSCs potential source for skin grafting

Study findings suggest that burn wound eschar-derived mesenchymal cells represent a population of multipotent stem cells, which could be a new resource for engineering approaches to heal burn wounds.

30 Jul 2012

HPV co-testing prospect for HIV-infected women

The risk for cervical precancer and cancer is similar in HIV-infected and HIV-uninfected women with normal cervical cytology and no evidence of oncogenic human papillomavirus infection, research shows.

30 Jul 2012

Hydroxychloroquine fails to modify HIV in patients not taking ART

The use of hydroxychloroquine does not reduce CD8 cell activation in HIV-infected patients not taking antiretroviral therapy, research shows.

30 Jul 2012

Conception plans miscarry with sperm DNA damage

Sperm with damaged DNA are more likely to cause spontaneous pregnancy loss, report researchers.

30 Jul 2012

New research indicates molecular signaling from end to end in peripheral nerve cells

When the longest cells in the body are injured at their farthest reaches, coordinating the cells' repair is no easy task. This is in part because these peripheral nerve cells can be extremely long - up to one meter in adult humans - which is a lot of distance for a molecular distress signal to cover in order to reach the "command center" of the cell's nucleus.

30 Jul 2012

Study sheds light on complexities of cancer genetics

By studying fruit flies, scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have successfully devised a fast and cost-saving way to uncover genetic changes that have a higher potential to cause cancer.

30 Jul 2012

Evidence for ADHD due to delay in brain development

Is attention-deficit/hyperactivity disorder (ADHD) due to a delay in brain development or the result of complete deviation from typical development? In the current issue of Biological Psychiatry, Dr. Philip Shaw and colleagues present evidence for delay based on a study by the National Institutes of Health.

30 Jul 2012

Biovest receives Rapporteur and Co-Rapporteur designation for BiovaxID personalized cancer vaccine

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has notified Biovest regarding the official designation of the Rapporteur and Co-Rapporteur for BiovaxID, a personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma.

30 Jul 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

Bruker introduces high-resolution microscope for research in biological dynamics

At the Microscopy & Microanalysis (M&M) 2012 Annual Meeting, Bruker today announced the Dimension FastScan Bio™ Atomic Force Microscope (AFM), which enables high-resolution microscopy research in biological dynamics.

From Bruker Nano Surfaces and Metrology 30 Jul 2012

FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas

Senesco Technologies, Inc. reported today that it was informed on July 26th that the U.S. Food and Drug Administration has granted orphan-drug designation for the company's lead drug candidate SNS01-T for treatment of both mantle cell lymphoma and diffuse large B-cell lymphoma.

30 Jul 2012

Some AIDS experts view health law coverage expansion with hope

Meanwhile, the Obama administration announced it would add new funds to increase access to HIV/AIDS care, but questions remain about whether it will be enough to address waiting lists for the drug assistance program. Also in the news, reports on treatment developments.

30 Jul 2012

Scientists identify new gene responsible for genetic form of blindness in newborns

One of the mysteries of blindness has been solved. A team of international scientists in collaboration with the Research Institute of the McGill University Health Centre (RI MUHC) identified a new gene responsible for Leber Congenital Amaurosis (LCA), a devastating genetic form of blindness in newborns.

30 Jul 2012

Antioxidants and pancreatic cancer risk: an interview with Dr Andrew Hart

The antioxidants that we mainly looked at were selenium, vitamin C and vitamin E. They are chemicals which inactivate pro-oxidants or free radicals. Smoking and normal metabolism can lead to the production of free radicals.

30 Jul 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter ended June 30, 2012.

30 Jul 2012

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

30 Jul 2012

FDA accepts Exelixis’ cabozantinib NDA for filing

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

30 Jul 2012

Cell News and Research

Gluconeogenesis severely compromised in HCC by IL6-Stat3-mediated activation of miR-23a

New drug shows promise for Long QT syndrome

Burn wound MSCs potential source for skin grafting

HPV co-testing prospect for HIV-infected women

Hydroxychloroquine fails to modify HIV in patients not taking ART

Conception plans miscarry with sperm DNA damage

New research indicates molecular signaling from end to end in peripheral nerve cells

Study sheds light on complexities of cancer genetics

Evidence for ADHD due to delay in brain development

Biovest receives Rapporteur and Co-Rapporteur designation for BiovaxID personalized cancer vaccine

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Bruker introduces high-resolution microscope for research in biological dynamics

FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas

Some AIDS experts view health law coverage expansion with hope

Scientists identify new gene responsible for genetic form of blindness in newborns

Antioxidants and pancreatic cancer risk: an interview with Dr Andrew Hart

Promising implications for improving cellular immunotherapy for treatment of cancer

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

FDA accepts Exelixis’ cabozantinib NDA for filing

How to optimize your cell line development eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics